Last reviewed · How we verify
NCT05974904
Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study
trial testing high-sensitivity C-reactive protein to albumin ratio in Metabolic Dysfunction-associated Fatty Liver Disease in 7,000 participants. Currently enrolling.
28 December 2026
Quick facts
| Lead sponsor | Chongqing Medical University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 7,000 |
| Start date | 18 July 2023 |
| Primary completion | 28 December 2026 |
| Estimated completion | 28 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- high-sensitivity C-reactive protein to albumin ratio
Conditions studied
- Metabolic Dysfunction-associated Fatty Liver Disease — all drugs for Metabolic Dysfunction-associated Fatty Liver Disease →
- Hepatic Steatosis — all drugs for Hepatic Steatosis →
- Liver Fibrosis — all drugs for Liver Fibrosis →
Sponsor
Chongqing Medical University
Who can join
Adults 18 to 90, any sex, with Metabolic Dysfunction-associated Fatty Liver Disease or Hepatic Steatosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic dysfunction-associated fatty liver disease (MAFLD). The main question\[s\] it aims to answer are: \[question 1\] Can hsCAR serve as a clinical indicator to determine whether a patient has MAFD? \[question 2\] Can hsCAR determine whether MAFLD patients are complicated with liver fibrosis?
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05974904
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metabolic Dysfunction-associated Fatty Liver Disease
Currently open trials in the same condition.
- NCT06541132 — Positive Association of US-FLI With the Severity of CAD · recruiting
Other Chongqing Medical University trials
Trials by the same sponsor.
- NCT07298889 — High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS · NA · recruiting
- NCT07503509 — Physiological Study of High PEEP in Noninvasive Ventilation · NA · recruiting
- NCT06118671 — The Evaluation of Artificial Intelligence in Lifestyle Management of Diabetic Patients in Community · NA · unknown
- NCT06272032 — Prospective Multicenter Observational Study and Promotion of the Application of Focused Ultrasound in Allergic Rhinitis · EARLY_PHASE1 · unknown
- NCT05974566 — Efficacy and Safety of Finerenone in Heart Failure With Reduced Ejection Fraction · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05974904 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chongqing Medical University
- Last refreshed: 12 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05974904.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing